- Letetresgene autoleucel🔍
- Long‐term safety and activity of NY|ESO‐1 SPEAR T cells after ...🔍
- CAR Therapy Era Moves Forward With Much Excitement🔍
- FDA Grants Afami|cel Accelerated Approval in Advanced Synovial ...🔍
- Adaptimmune leads soft tissue sarcoma therapy with TCR approval🔍
- Developmental Therapeutics — Immunotherapy🔍
- Enhanced T Cell Therapy Found Effective against Multiple Solid ...🔍
- Supplementary appendix🔍
Adaptimmune's Lete|cel Achieves Primary Endpoint in Pivotal Trial
Letetresgene autoleucel - Drug Targets, Indications, Patents - Synapse
Related. 12. Clinical Trials associated with Letetresgene autoleucel ... This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel ...
Long‐term safety and activity of NY-ESO‐1 SPEAR T cells after ...
Here, we describe long-term clinical outcomes and expanded correlative translational studies ... The main study times were: day 0, ASCT (stem cell ...
CAR Therapy Era Moves Forward With Much Excitement, Lingering ...
CAR T-cell therapies have displayed extraordinarily high response rates in pivotal clinical trials. ... The trial met its primary end point of CR ...
FDA Grants Afami-cel Accelerated Approval in Advanced Synovial ...
About 90 patients were evenly split into cohorts 1 and 2 and treated in the study. With the main efficacy analysis focused on cohort 1, cohort 2 ...
Adaptimmune leads soft tissue sarcoma therapy with TCR approval
... cell surface antigens and intracellular antigens. In addition to Tecelra, AdaptImmune's pipeline TCR therapy lete-cel met its primary efficacy ...
This supports the potential of lete-cel as a novel therapy for pts with advanced or metastatic SyS and MRCLS. Clinical trial information: NCT03967223. Research ...
Enhanced T Cell Therapy Found Effective against Multiple Solid ...
A first-in-human clinical trial of an enhanced T cell therapy that targets multiple solid tumors bearing the antigen MAGE-A4, ...
Supplementary appendix - The Lancet
The primary clinical endpoint for efficacy ... Clinical trials investigating the efficacy and safety of adoptive T cell therapy are ongoing and.
Adaptimmune Q1 2024 Financial and Business Updates
The pivotal IGNYTE-ESO trial for lete-cel has met its primary efficacy endpoint, with full analyses expected by late 2024. Adaptimmune ...
Idecabtagene vicleucel for relapsed and refractory multiple myeloma
The study met its primary endpoint with low rates of grade 3/grade 4 ... cell therapy clinical trial. In contrast to recent ...
Adaptimmune cell therapy hits key goal in pivotal sarcoma study
The data show that 42% of patients (27/64) patients experienced clinical responses—meeting the study's primary endpoint—with six complete ...
TCR² Therapeutics Announces Clinical Trial Collaboration ...
The primary objective of the Phase 2 trial is to evaluate the efficacy of gavo-cel in patients with unresectable, metastatic or recurrent ...
Adaptimmune outlines new strategy amid Tecelra launch
The positive results from this pivotal trial, which has met its primary endpoint ... clinical trial, the pivotal trial for lete-cel.
Autologous Cell Therapies Hit Their Stride in Solid Tumors
The clinical dataset that Adaptimmune submitted to the FDA for afami-cel ... In a Phase II clinical trial, Imvax is temporarily implanting ...
FDA Grants Accelerated Approval to Afamitresgene Autoleucel ...
Clinical trials using NY-ESO-1 ... Afami-cel was then administered as a single intravenous infusion. Primary Endpoint and Efficacy Results.
Biotech and Medical Tech Stocks and the Hunt for Cancer Treatments
As a reminder, the primary endpoint of the approximate nine to ... Lete-cel builds on the potential of Adaptimmune's sarcoma franchise ...
... primary endpoint from its pivotal trial conducted by our. Page 5 ... That pivotal trial was conducted in synovial sarcoma and myxoid round cell ...
Biotech And Medical Tech Stocks And The Hunt For Cancer ...
As a reminder, the primary endpoint of the approximate nine to ... Lete-cel builds on the potential of Adaptimmune's sarcoma franchise ...
Biotech and Medical Tech Stocks Report Significant Updates in the ...
As a reminder, the primary endpoint of the approximate nine to ... Lete-cel builds on the potential of Adaptimmune's sarcoma franchise ...
Biotech and Medical Tech Stocks Report Significant Updates in the ...
As a reminder, the primary endpoint of the approximate nine to 18-patient ... Lete-cel builds on the potential of Adaptimmune's sarcoma franchise to ...